Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment

  title={Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment},
  author={Guy Chouinard and Lawrence. Annable and Andr{\'e}e Ross-Chouinard and Madeleen Olivier and F Fontaine},
In a 12-week double-blind study, piracetam at two dose levels (2.4 and 4.8g/day) was compared to placebo in the treatment of 60 elderly psychiatric patients with mild diffuse cerebral impairment, but no signs of focal brain lesion. The psychiatric illness, schizophrenia or affective disorder, of patients selected was in remission at the time of the study. Monthly evaluations by the nurse revealed that piracetam improved overall functioning, particularly alertness, socialization, and cooperation… 

Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis

The results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.

Does the Addition of Piracetam Safely and Effectively Improve Behavioral and or Cognitive Functions in Schizophrenia

There requires a continued and more updated investigation to be aimed at determining a specific dose of piracetam therapy, a specific patient population for which Piracetam is most effective and to further elaborate its safety profile outside a controlled research setting.

Antipsychotic medication for elderly people with schizophrenia.

Antipsychotics may be widely used in the treatment of elderly people with schizophrenia, however, based on this systematic review, there is little robust data available to guide the clinician with respect to the most appropriate drug to prescribe.

Piracetam: a review of pharmacological properties and clinical uses.

  • B. Winblad
  • Medicine, Psychology
    CNS drug reviews
  • 2005
Piracetam, a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), has a variety of physiological effects that may result from the restoration of cell membrane fluidity, and its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia.

Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia

Present evidence suggests some therapeutic efficacy for nootropics and metabolically active compounds as well as alkylxanthines in the treatment of dementia.

Recent uses of piracetam in pediatric neurology

Recent uses of piracetam in pediatric neurology is reported on in the International Journal of Clinical Case Reports and Reviews.

Peptide analogs of pyracetam as ligands for hypothetical nootropic receptors

Pyracetam is used in medicine for improving intellectual and memory function in children with retarded intellectual development, to reduce the severity of the psycho-organic syndrome in cerebral changes due to aging, and to improve the rate of restoration of memory in patients with traumatic or cerebrovascular disturbances.

Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats

Four so-called cognitive enhancers, all widely used for the treatment of the symptoms associated with mental aging, cerebral insufficiency and senile memory disorder, were investigated in this passive avoidance paradigm and Piracetam, an extract of Ginkgo biloba, dihydroergocristine and a combination of raubasine with dihydromine, all attenuated the amnesia induced by scopolamine.

Recent Uses of Piracetam in Pediatric Neurology.

Abstract Piracetam (2-oxo-1-pyrrolidine acetamide) is a cyclical derivative of GABA (gamma-aminobutyric acid). It was first synthesized during the 1950s by Corneliu E. Giurgea. There are reports of

Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics

In the light of new observations showing increased cortisol concentrations in Alzheimer patients, this steroid dependency of the effects of memory enhancers might explain why only a limited number of these patients respond to therapy with nootropics or cholinomimetics.



Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia

The effects of piracetam (Nootropil®, UCB 6215) on mental functions and on regional cerebral blood flow (rCBF) were investigated in eight patients in the presenile age who displayed symptoms of

Piracetam in chronic brain failure.

A double-blind, placebo-controlled trial was carried out on 109 aged patients with minimal or with moderate chronic brain failure to assess the effectiveness of piracetam in preventing the progression of dementia, and the findings do not support the usefulness of pir acetam in the treatment of such patients.

Piracetam in the treatment of post-concussional syndrome. A double-blind study.

In the author's opinion, piracetam seems to be a promising new drug for the treatment of post-concussional syndrome.

A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory.

Fifty-six hospitalized geriatric patients between the ages of 65 and 80 were given piracetam (Nootropil) 2400 mg/day or placebo on a double blind basis over a two month period and there were no significant statistical differences.

[Piracetam and vigilance. A study of EEG changes and clinical effects in gerontopsychiatric patients (author's transl)].

The statistical analysis of the resulting factor scores shows that piracetam induces significant EEG changes: decrease of slow frequencies, augmentation and acceleration of alpha-activity and increase of beta-activity, indicating an increase in vigilance.

Some effects of piracetam (UCB 6215 nootropyl) on chronic schizophrenia

Some cognitive improvement but little if any change in the disease state of the patient is suggested by a study of effects of a nootropic drug on chronic schizophrenia.

Antipsychotic Drugs

Antipsychotic drugs have been used clinically for 50 years, and the first agents introduced, such as chlorpromazine, revolutionized the practice of psychiatry, reflecting significant degrees of success in enhancing potency and diminishing undesirable side effects.

A double-blind study on the effects of piracetam upon perceptual and psychomotor performance at varied heart rates in patients treated with artificial pacemakers

Results indicate that Piracetam had some protective effect against the influence of an assumed cerebral hypoxia at the lower rate or a cortical arousing effect, which counteracted the decrement in vigilance associated with the slow heart rate.


In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients, found to be equally effective in controlling parkinsonian symptoms and as efficacious as procyclidine, their previous antiparkinsonian drug.

Effect of piracetam on EEG spectra of boys with learning disorders

Power spectral analyses revealed that piracetam caused a decrease in the amount of delta activity and an increase in the average EEG frequency, which is in agreement with those obtained by other workers in adult patients.